Advertisement


John V. Cox, DO, MBA, on 2017 Quality Care Symposium Highlights: Expert Perspective

2017 Quality Care Symposium

Advertisement

John V. Cox, DO, MBA, of the Parkland Health System/UTSW, discusses some of the key presentations at the 2017 Quality Care Symposium (Abstracts 3, 37, 52).



Related Videos

Issues in Oncology

Julie Bryar Porter, MS, on Improving Care: One Center’s Experience

Julie Bryar Porter, MS, of Stanford Health Care, discusses an approach to improving patient care with physician-led quality measures from diagnosis through end of life implemented at her academic cancer center (Abstract 49).

Issues in Oncology

Gabrielle Rocque, MD, on The Oncology Care Model: Transforming Practices

Gabrielle Rocque, MD, of the University of Alabama at Birmingham, discusses the challenges of implementing Oncology Care Model requirements, such as providing treatment plans, and the opportunities to transform practices with improved workflow and patient outcomes.

Issues in Oncology

Gwendolyn P. Quinn, PhD, on Underserved Cancer Patients and Survivors: Are We Listening to Them?

Gwendolyn P. Quinn, PhD, of Moffitt Cancer Center, discusses the challenges that minority, LGBTQ, low-literacy, and underserved populations face in getting their voices heard and what it will take to change that.

Issues in Oncology

Brian Weiss, MD, on Reducing Treatment Errors With Improvement Science

Brian Weiss, MD, of Cincinnati Children’s Hospital Medical Center, discusses a program designed to eliminate errors in chemotherapy use among pediatric patients whose regimens incorporate multiple drugs and rigorous monitoring schedules (Abstract 37).

Issues in Oncology
Lung Cancer

Thomas J. Smith, MD, on Oral Abstract Session B (2017 Quality Care Symposium)

Thomas J. Smith, MD, of the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, summarizes two papers for which he was a discussant: reducing overuse of colony-stimulating factors without compromising the safety of patients with lung cancer receiving chemotherapy, and a cost-and-survival analysis before and after implementing Dana-Farber Clinical Pathways for patients with stage IV non–small cell lung cancer (Abstracts 3, 52).

Advertisement

Advertisement




Advertisement